Rapamycin impairs HPD-induced beneficial effects on glucose homeostasis

摘要: Background and Purpose Rapamycin, which is used clinically to treat graft rejection, has also been proposed have an effect on metabolic syndrome; however, very little information available its effects in lean animals/humans. The purpose of this study was characterize further the continuous use rapamycin glucose homeostasis C57BL6/J mice. Experimental Approach Mice were fed a high-protein diet (HPD) for 12 weeks develop model then treated daily with 5 while remaining HPD. Metabolic parameters, endocrine profiles, tolerance tests, insulin sensitivity index, expression transporter GLUT4 chromium distribution measured vivo. Key Results Lower body weight gain as well decreased caloric intake, fat pads, fatty liver scores, adipocyte size test values observed HPD-fed mice compared high-fat or standard diet. Despite these beneficial effects, rapamycin-treated showed greater intolerance, reduced sensitivity, lower muscle changes levels tissues even high levels. Conclusion Implications Our findings demonstrate that administration may lead development diabetes syndrome, it found induce hyperglycaemia intolerance animal model.